Multiple Sclerosis Therapeutics Market to Grow at a CAGR of 6.5% to reach US$ 39,223.59 Million from 2020 to 2027
2019 年多发性硬化症治疗市场价值为 240.269 亿美元,预计到 2027 年将达到 392.2359 亿美元;预计 2020 年至 2027 年的复合年增长率为 6.5%。
多发性硬化症 (MS) 是一种影响中枢神经系统的自身免疫性疾病。免疫系统攻击神经,导致大脑与身体其他部位之间的沟通出现问题。免疫抑制剂和免疫调节剂以及物理疗法被广泛用于治疗 MS。
多发性硬化症治疗市场的范围包括药物类别、给药途径、分销渠道和地区。多发性硬化症治疗市场分析基于北美、欧洲、亚太地区、中东和非洲以及南美和中美等地区。该报告对多发性硬化症治疗市场进行了深入分析,重点关注各种参数,例如市场趋势、技术进步、市场动态以及全球主要市场参与者的竞争格局分析。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
多发性硬化症治疗市场:
Multiple Sclerosis Therapeutics Market: Strategic Insights
Multiple Sclerosis Therapeutics Market
-
CAGR (2019 - 2027)
6.5%
-
Market Size 2019
US$ 24.03 Billion
-
Market Size 2027
US$ 39.22 Billion
Market Dynamics
GROWTH DRIVERS
- XXXXXXX
- XXXXXXX
- XXXXXXX
FUTURE TRENDS
- XXXXXXX
- XXXXXXX
- XXXXXXX
OPPORTUNITIES
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Merck Co Inc
- Novartis AG
- Bayer AG
- Sanofi
- Bristol Myers Squibb Company
- Horizon Therapeutics plc
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F HOFFMANN LA ROCHE LTD
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
- 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
- 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
Market Segmentation
药物类别(免疫抑制剂和免疫调节剂)
给药途径(注射和口服)
分销渠道(医院药房、零售药房和电子商务)
地理(北美洲、欧洲、亚太地区、中东和非洲、南美洲和中美洲)
Multiple Sclerosis Therapeutics Market: Strategic Insights
-
CAGR (2019 - 2027)6.5% -
Market Size 2019
US$ 24.03 Billion -
Market Size 2027
US$ 39.22 Billion
Market Dynamics
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Merck Co Inc
- Novartis AG
- Bayer AG
- Sanofi
- Bristol Myers Squibb Company
- Horizon Therapeutics plc
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F HOFFMANN LA ROCHE LTD
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
- 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
- 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
Market Segmentation
复合年增长率(2019 - 2027 年)6.5%- 2019 年市场规模
240.3 亿美元 - 2027 年市场规模
392.2 亿美元
市场动态
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
关键人物;主力;重要一员
- 默克公司
- 诺华公司
- 拜耳公司
- 赛诺菲
- 百时美施贵宝公司
- Horizon Therapeutics plc 。
- 梯瓦制药工业有限公司
- 武田药品工业株式会社
- F.霍夫曼-拉罗氏有限公司
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 免疫抑制剂和免疫调节剂
- 注射和口服
- 医院药房
- 零售药店
- 电子商务
- 北美
- 欧洲
- 亚太地区
- 中东和非洲
- 南美洲和中美洲
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
市场洞察
多发性硬化症患病率不断上升
多发性硬化症是一种影响大脑、脊髓和视神经的慢性疾病。多发性硬化症的症状包括虚弱、焦虑、味觉异常、感觉减退、视力模糊或视力丧失。其他症状包括便秘、肌肉僵硬、抑郁、思维问题和泌尿问题。
研究表明,全球多发性硬化症的患病率正在上升。例如,根据美国国家多发性硬化症协会 2017 年的研究,美国约有 100 万名成年人(高达 913,925 人)患有多发性硬化症。2010 年,该病的患病率估计为每 100,000 人中有 309 例,也就是说,有 727,344 名成年人患有多发性硬化症。此外,根据加拿大政府的数据(2014-2015 年估计),超过 77,000 名加拿大人患有多发性硬化症,其中四分之三是女性。
此外,多发性硬化症协会估计,2018 年英国约有 110,000 人患有多发性硬化症。该协会还提到,女性患多发性硬化症的几率是男性的两倍多。每年确诊的新患者数量也在增加;从 2017 年的 5,000 人增加到 2018 年的 6,700 人。
因此,多发性硬化症患病率的不断上升正在推动多发性硬化症治疗市场的发展。
基于药物类别的见解
根据多发性硬化症治疗药物类别,多发性硬化症治疗市场细分为免疫抑制剂和免疫调节剂。2019 年,免疫调节剂细分市场占据了较大的市场份额。该细分市场的增长归因于新仿制药的推出以及 MS 治疗中免疫调节剂的采用增加。预测期内,免疫抑制剂细分市场的复合年增长率可能会更高。
基于给药途径的见解
就给药途径而言,多发性硬化症治疗市场分为注射剂和口服剂。2019 年,注射剂占据了较大的市场份额,预计同一细分市场在预测期内的复合年增长率将更高。
基于分销渠道的洞察
根据分销渠道,多发性硬化症治疗市场分为医院药房、零售药房和电子商务。医院药房部分在 2019 年占据了最大的市场份额,预计电子商务部分在预测期内将实现最高的复合年增长率。
COVID-19 疫情已成为全球面临的最大挑战。这一挑战将尤其令人担忧,尤其是对全球发展中国家而言,因为它将导致全球贸易中断,从而导致进口减少。迄今为止,尚未找到针对 COVID 19 的明确治疗方法。患有神经系统疾病等严重疾病的患者正在经历此类慢性疾病治疗的延误。与此次疫情相关的供应链中断最终将在短期内影响产品的销售。然而,由于封锁期间药店获准营业,因此 MS 药物的供应在疫情期间一直保持稳定。为应对 COVID-19 疫情,多家公司正在削减临床试验活动并推迟产品发布。例如,由于 COVID-19 疫情的爆发,百时美施贵宝推迟了其多发性硬化症药物 Zeposia (ozanimod) 的上市。
公司通常会采用产品发布和扩张策略来扩大其全球业务范围并满足不断增长的需求。市场参与者通常会采用这些策略来扩大其产品组合。
多发性硬化症治疗市场中的市场参与者采用产品创新战略来满足全球不断变化的客户需求,这也使参与者能够在全球范围内维护其品牌名称。
多发性硬化症治疗市场报告范围
报告属性 | 细节 |
---|---|
2019 年市场规模 | 240.3亿美元 |
2027 年市场规模 | 392.2亿美元 |
全球复合年增长率(2019 - 2027) | 6.5% |
历史数据 | 2017-2018 |
预测期 | 2020-2027 |
涵盖的领域 | 按药物类别
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
按药物类别
- 免疫抑制剂
- 免疫调节剂
按给药途径
- 注射剂
- 口服
按分销渠道
- 医院药房
- 零售药店
- 电子商务
按地理位置
- 北美
- 我们
- 加拿大
- 墨西哥
- 欧洲
- 法国
- 德国
- 意大利
- 英国
- 西班牙
- 欧洲其他地区
- 亚太地区 (APAC)
- 中国
- 印度
- 韩国
- 日本
- 澳大利亚
- 亚太其他地区
- 中东和非洲 (MEA)
- 南非
- 沙特阿拉伯
- 阿联酋
- 中东和非洲其他地区
- 南美洲 (SAM)
- 巴西
- 阿根廷
- 南美洲其他地区
公司简介
- 默克公司
- 诺华公司
- 拜耳公司
- 赛诺菲
- 百时美施贵宝公司
- Horizon Therapeutics plc 。
- 梯瓦制药工业有限公司
- 武田药品工业株式会社
- F.霍夫曼-拉罗氏有限公司
- 百健(Biogen)
Multiple Sclerosis Therapeutics Market Report Scope
Report Attribute | Details |
---|---|
Market size in | US$ 24.03 Billion |
Market Size by | US$ 39.22 Billion |
Global CAGR | 6.5% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By 药物类别(免疫抑制剂和免疫调节剂) |
Regions and Countries Covered |
北美(美国、加拿大、墨西哥)
|
Market leaders and key company profiles |
|
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
The List of Companies - Multiple Sclerosis Therapeutics Market
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD.
- Biogen
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.